Business Context and Reporting Period
Company: eXoZymes Inc. (Nasdaq: EXOZ)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: eXoZymes is a pre-revenue biotechnology company developing a synthetic biology platform for scalable production of chemical molecules. The company operates as a single reportable segment focused on research and commercialization of exozyme biosolutions. It completed its IPO in November 2024 and is classified as an Emerging Growth Company and Smaller Reporting Company.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2024 |
|---|---|---|---|
| Operating Income | $0 | $0 | $0 |
| Net Loss | $(2,286,991) | $(6,503,698) | $(4,025,361) |
| Net Loss Per Share (Basic & Diluted) | $(0.27) | $(0.78) | $(0.64) |
| Cash and Cash Equivalents (Sept 30, 2025) | $5,098,687 | ||
| Working Capital (Sept 30, 2025) | $4,391,664 | ||
| Total Assets (Sept 30, 2025) | $7,719,049 | ||
| Total Liabilities (Sept 30, 2025) | $2,344,627 | ||
| Stockholders' Equity (Sept 30, 2025) | $5,374,422 |
Cash Flow (Nine Months Ended Sept 30, 2025):
- Net cash used in operating activities: $(4,528,240)
- Net cash used in investing activities: $(75,228)
- Net cash used in financing activities: $(17,155)
Material Changes vs. Prior Period
- Revenue: The company remains pre-revenue with $0 operating income for both the current and prior periods.
- Net Loss: Net loss increased by 61.6% for the nine months ended September 30, 2025, compared to the same period in 2024. The three-month loss increased by 38.1%.
- Operating Costs: Total operating costs rose 77.8% year-over-year for the nine-month period.
- General & Administrative (G&A): Increased 63.3% due to higher compensation (new hires not covered by grants), professional fees, and D&O insurance costs.
- Research & Development (R&D): Increased 109.5% primarily due to new hires, higher salaries, stock-based compensation, and a reduction in grant funding offsets.
- Liquidity: Cash and cash equivalents decreased by 47.5% from December 31, 2024 ($9.7M) to September 30, 2025 ($5.1M), reflecting the burn rate from operations.
- Grants: Grants receivable decreased by 59.0% to $302,643 due to the completion of certain grants and timing of drawdowns. However, the company recognized a discrete income tax benefit of $105,826 in Q3 2025 from amended tax returns.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern due to anticipated funding shortfalls and pre-revenue status. The ability to meet long-term obligations depends on securing additional financial support.
- Capital Resources: The company utilized IPO proceeds (approx. $15.2M net) to repay related party loans and fund operations. It currently holds approximately $5.1M in cash. No current arrangements for additional funding exist.
- Unusual Items:
- Tax Benefit: A $105,826 income tax receivable was recorded in Q3 2025 following the enactment of the "One Big Beautiful Bill Act" (OBBBA), which allowed immediate expensing of R&D expenditures for 2022 and 2023.
- Stock-Based Compensation: Significant non-cash expense of $1.31M for the nine months ended Sept 30, 2025, driven by option grants and RSUs.
- Risks:
- Regulatory/Trade: Potential adverse effects from U.S. tariff changes, trade policy shifts, and restrictions on federal research grants.
- Technology: Uncertainty regarding the commercial viability and regulatory approval of the synthetic biology platform.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting, though remediation efforts are underway.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.1M cash balance against the current burn rate of approx. $4.5M per nine months to assess the timeline for potential dilution or debt financing.
- Grant Dependency: Confirm the status and renewal likelihood of government grants (DOE, NIH, NSF), as a reduction in these offsets significantly increased net R&D expenses.
- Going Concern Status: Review management's specific plans for securing additional capital to address the "substantial doubt" disclosure.
- Internal Controls: Monitor the progress of remediation for the disclosed material weaknesses in financial reporting controls.
- Stock-Based Compensation: Assess the impact of the $3.07M in unrecognized stock-based compensation on future earnings.